Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (25201)
All Articles published online
|
Publishing Process of This Article
|
May 21, 2016 (publication date) through Mar 28, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol 2016; 22(19): 4619-4625 [PMID: 27217694 DOI: 10.3748/wjg.v22.i19.4619] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i19/4619.htm |
| Number | Citing Articles |
| 1 |
Lu Xue, Nita J. Maihle, Xiaolin Yu, Shou-Ching Tang, Hong Yan Liu. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth. Molecular Pharmaceutics 2018; 15(11): 4801 doi: 10.1021/acs.molpharmaceut.8b00388
|
| 2 |
Phei Er Saw, Er-Wei Song. Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein & Cell 2019; 10(11): 787 doi: 10.1007/s13238-019-0639-7
|
| 3 |
Zulrahman Erlangga, Katharina Wolff, Tanja Poth, Alexander Peltzer, Sven Nahnsen, Steffi Spielberg, Kai Timrott, Norman Woller, Florian Kühnel, Michael P. Manns, Anna Saborowski, Arndt Vogel, Michael Saborowski. Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. Cancers 2019; 11(12): 1904 doi: 10.3390/cancers11121904
|
| 4 |
Xiao Guan, Na Lu, Jianping Zhang. Evaluation of Epidermal Growth Factor Receptor 2 Status in Gastric Cancer by CT-Based Deep Learning Radiomics Nomogram. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.905203
|
| 5 |
Chenzhe Ma, Xiao Wang, Jiwu Guo, Bo Yang, Yumin Li. Challenges and future of HER2-positive gastric cancer therapy. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1080990
|
| 6 |
Saurav Verma, Amanda Chapman, Lee-Anne Pickard, Danielle Porplycia, Haley McConkey, Patricia Jarosz, James Sinfield, Carolyn Lauzon-Young, Matthew J Cecchini, Christopher Howlett, Natalie Grindrod, Bekim Sadikovic, Stephen A Welch, Daniel Breadner. Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort. Exploration of Targeted Anti-tumor Therapy 2024; 5(5): 1100 doi: 10.37349/etat.2024.00265
|
| 7 |
Brian C. Grieb, Rajiv Agarwal. HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. Current Treatment Options in Oncology 2021; 22(10) doi: 10.1007/s11864-021-00884-7
|
| 8 |
Pandiyaraj Kanagavalli, Shimaa Eissa. Redox probe-free electrochemical immunosensor utilizing electropolymerized melamine on reduced graphene oxide for the point-of-care diagnosis of gastric cancer. Talanta 2024; 270: 125549 doi: 10.1016/j.talanta.2023.125549
|
| 9 |
Maria Del Carmen Rodriguez Pena, Alcides Chaux, Marie-Lisa Eich, Aline C. Tregnago, Diana Taheri, Walaa Borhan, Rajni Sharma, M. Katayoon Rezaei, George J. Netto. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Archiv 2019; 475(3): 349 doi: 10.1007/s00428-019-02618-5
|
| 10 |
Christiana Mo, Michelle Sterpi, Hyein Jeon, Fernand Bteich. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies. Cancers 2024; 16(16): 2854 doi: 10.3390/cancers16162854
|
| 11 |
Yue Wang, Yang Yu, Wei Han, Ying-Jing Zhang, Lin Jiang, Hua-Dan Xue, Jing Lei, Zheng-Yu Jin, Jian-Chun Yu. CT Radiomics for Distinction of Human Epidermal Growth Factor Receptor 2 Negative Gastric Cancer. Academic Radiology 2021; 28(3): e86 doi: 10.1016/j.acra.2020.02.018
|
| 12 |
James Kalmuk, Dan Rinder, Carl Heltzel, Albert Craig Lockhart. An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic. Expert Opinion on Drug Discovery 2022; 17(5): 427 doi: 10.1080/17460441.2022.2050692
|
| 13 |
Matthew S. Strand, Albert Craig Lockhart, Ryan C. Fields. Genetics of Gastric Cancer. Surgical Clinics of North America 2017; 97(2): 345 doi: 10.1016/j.suc.2016.11.009
|
| 14 |
Qing Xu, Zhuomin Yin, Yueqi Li, Xiu Zhu, Hanmei Lou, Juan Ni. Prognostic value of HER2 expression in cervical adenocarcinoma: A retrospective cohort study. Oncology Letters 2025; 29(5): 1 doi: 10.3892/ol.2025.14963
|
| 15 |
Ling Yin. Genome Editing - Recent Advances and Applications [Working Title]. 2025; doi: 10.5772/intechopen.1008441
|
| 16 |
舒畅 张. Imaging Progress of Human Epidermal Growth Factor Receptor 2 in Gastric Cancer. Advances in Clinical Medicine 2022; 12(06): 5136 doi: 10.12677/ACM.2022.126744
|
| 17 |
Hiroshi Saeki, Eiji Oki, Tomomi Kashiwada, Takaaki Arigami, Akitaka Makiyama, Masaaki Iwatsuki, Yukiya Narita, Hironaga Satake, Yoshiko Matsuda, Hideto Sonoda, Mototsugu Shimokawa, Yoshihiko Maehara. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). European Journal of Cancer 2018; 105: 41 doi: 10.1016/j.ejca.2018.09.024
|
| 18 |
Astrid E. Slagter, Marieke A. Vollebergh, Edwin P. M. Jansen, Johanna W. van Sandick, Annemieke Cats, Nicole C. T. van Grieken, Marcel Verheij. Towards Personalization in the Curative Treatment of Gastric Cancer. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.614907
|
| 19 |
Wenqin Feng, Ryotaku Inoue, Takeshi Kuwata, Naoki Niikura, Satoshi Fujii, Nobue Kumaki, Kokichi Honda, Li-An Xu, Aaron Goetz, Patricia Gaule, John Cogswell, David L. Rimm, Robert McGee. Assessment of the Impact of Alternative Fixatives on HER2 Detection in Breast Cancer and Gastric Cancer Tumor Specimens. Applied Immunohistochemistry & Molecular Morphology 2023; 31(5): 339 doi: 10.1097/PAI.0000000000001126
|
| 20 |
Rachel E. Sexton, Mohammed Najeeb Al Hallak, Md. Hafiz Uddin, Maria Diab, Asfar S. Azmi. Gastric Cancer Heterogeneity and Clinical Outcomes. Technology in Cancer Research & Treatment 2020; 19 doi: 10.1177/1533033820935477
|
| 21 |
Yin Li, Wei-Gang Dai, Qingyu Lin, Zeyao Wang, Hai Xu, Yuying Chen, Jifei Wang. Predicting human epidermal growth factor receptor 2 status of patients with gastric cancer by computed tomography and clinical features. Gastroenterology Report 2023; 12 doi: 10.1093/gastro/goae042
|
| 22 |
Wenwen Zhang, Tianbo Liu, Liangliang Jiang, Jiarong Chen, Qiuli Li, Jing Wang. Immunogenic cell death-related gene landscape predicts the overall survival and immune infiltration status of ovarian cancer. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.1001239
|
| 23 |
He-Wei Zhang, Ying Guo, Lin-xiao Sun, Fu-biao Ni, Ke Xu. Prognostic value of small mother against decapentaplegic expression in human gastric cancer. Bioengineered 2021; 12(1): 2534 doi: 10.1080/21655979.2021.1935192
|
| 24 |
Honoka Yamamoto, Takeshi Nakanishi, Kan-ichiro Ihara, Taro Tachibana, Chikako Yokoyama. Generation of Rat Monoclonal Antibodies Against Human Epidermal Growth Factor Receptor 2. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2023; 42(2): 59 doi: 10.1089/mab.2022.0042
|
| 25 |
Xiaoqing Cheng. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes 2024; 15(7): 903 doi: 10.3390/genes15070903
|
| 26 |
Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduction and Targeted Therapy 2024; 9(1) doi: 10.1038/s41392-024-01735-1
|
| 27 |
Salvador Gomez, Allan Tsung, Zhiwei Hu. Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer. Molecules 2020; 25(21): 4964 doi: 10.3390/molecules25214964
|
| 28 |
Kanwal P.S. Raghav, Mark M. Moasser. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Clinical Cancer Research 2023; 29(13): 2351 doi: 10.1158/1078-0432.CCR-22-0283
|
| 29 |
Chiara Arienti, Sara Pignatta, Anna Tesei. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.01308
|
| 30 |
Shadi A. Esfahani, Carolina de Aguiar Ferreira, Nicholas J. Rotile, Bahar Ataeinia, Shriya Krishna, Onofrio A. Catalano, Peter Caravan, Yi-Fen Yen, Pedram Heidari, Umar Mahmood. HER3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in Gastric Cancer. Molecular Imaging and Biology 2023; 25(2): 353 doi: 10.1007/s11307-022-01763-9
|
| 31 |
Maria Bonomi, Daniele Spada, Gian Luca Baiocchi, Andrea Celotti, Matteo Brighenti, Giulia Grizzi. Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice. International Journal of Molecular Sciences 2024; 25(7): 3876 doi: 10.3390/ijms25073876
|
| 32 |
Antonella Cammarota, Rachel Woodford, Elizabeth C. Smyth. Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight. Drugs 2025; 85(3): 361 doi: 10.1007/s40265-024-02132-2
|
| 33 |
Zi-Ning Lei, Qiu-Xu Teng, Qin Tian, Wei Chen, Yuhao Xie, Kaiming Wu, Qianlin Zeng, Leli Zeng, Yihang Pan, Zhe-Sheng Chen, Yulong He. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01190-w
|
| 34 |
Advera Ngaiza, Edda Vuhahula, James Yahaya, Marie Claire Ndayisaba, Gerald J. Kawishe, James P. Grenert, Li Zhang, Katherine Van Loon, Dianna L. Ng. Evaluation of Human Epidermal Growth Factor Receptor 2 Expression in Gastric and Gastroesophageal Cancers in Tanzania. Archives of Pathology & Laboratory Medicine 2022; 146(12): 1523 doi: 10.5858/arpa.2021-0394-OA
|
| 35 |
Moonsik Kim, An Na Seo. Molecular Pathology of Gastric Cancer. Journal of Gastric Cancer 2022; 22(4): 264 doi: 10.5230/jgc.2022.22.e35
|
| 36 |
Heidi C. Ko, Kyle C. Strickland, Dana Jaggessarsingh, Alicia Dillard, Michelle Green, Erin Newburn, Tiffany Sellaro, Jonathan L. Klein, Brian Caveney, Marcia Eisenberg, Eric A. Severson, Shakti Ramkissoon, Rebecca A. Previs, Anis Toumeh. From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates. Frontiers in Oncology 2025; 15 doi: 10.3389/fonc.2025.1565872
|
| 37 |
Maria Alsina Maqueda, Ana Teijo Quintáns, Miriam Cuatrecasas, Maria Jesús Fernández Aceñero, Ana Fernández Montes, Carlos Gómez Martín, Paula Jiménez Fonseca, Carolina Martínez Ciarpaglini, Fernando Rivera Herrero, Mar Iglesias Coma. Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clinical and Translational Oncology 2025; doi: 10.1007/s12094-025-03865-6
|
| 38 |
Pedro A. Hermida De Viveiros, Imran Nizamuddin, George Kalapurakal, Amir Behdad, Massimo Cristofanilli, Devalingam Mahalingam. Precision Oncology. Advances in Oncology 2021; 1: 97 doi: 10.1016/j.yao.2021.02.009
|
| 39 |
Wen-Long Guan, Ye He, Rui-Hua Xu. Gastric cancer treatment: recent progress and future perspectives. Journal of Hematology & Oncology 2023; 16(1) doi: 10.1186/s13045-023-01451-3
|
| 40 |
Ali Abdulnabi Suwaidan, David K. Lau, Ian Chau. HER2 targeted therapy in colorectal cancer: New horizons. Cancer Treatment Reviews 2022; 105: 102363 doi: 10.1016/j.ctrv.2022.102363
|
| 41 |
Farideh Hashemi, Fatemeh Tajik, Leili Saeednejad Zanjani, Masoumeh Dehghan Manshadi, Sadegh Safaei, Pegah Babaheidarian, Fahimeh Fattahi, Roya Ghods, Zahra Madjd. Clinical significance of Talin-1 and HER-2 status in different types of gastric carcinoma. Biomarkers 2024; 29(8): 539 doi: 10.1080/1354750X.2024.2423270
|
| 42 |
Chen Xu, Yalan Liu, Dongxian Jiang, Qian Li, Xiaowen Ge, Ying Zhang, Jie Huang, Jieakesu Su, Yuan Ji, Jun Hou, Shaohua Lu, Yingyong Hou, Tianshu Liu. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type. Oncotarget 2017; 8(20): 33185 doi: 10.18632/oncotarget.16567
|
| 43 |
Zhuang Luo, Yong Chen, Bangquan Chen, Ziming Zhao, Rongfan Wu, Jun Ren. GGT5 facilitates migration and invasion through the induction of epithelial–mesenchymal transformation in gastric cancer. BMC Medical Genomics 2024; 17(1) doi: 10.1186/s12920-024-01856-0
|
| 44 |
Chen Xu, Miaomiao Sun, Mei Jin, Zengshan Li, Rong Qin, Guoping Ren, Wenyong Sun, Lirong Chen, Lijuan Luan, Yalan Liu, Dongxian Jiang, Lingli Chen, Rongkui Luo, Yingyong Hou. Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China. Diagnostic Pathology 2022; 17(1) doi: 10.1186/s13000-022-01230-7
|
| 45 |
Anupam DHASMANA, Swati DHASMANA, Sudhir KOTNALA, A ANUKRITI, Vivek K. KASHYAP, Poornima D. SHAJI, Partha LASKAR, Sheema KHAN, Rinaldo PELLICANO, Sharmila FAGOONEE, Shafiul HAQUE, Murali M. YALLAPU, Subhash C. CHAUHAN, Meena JAGGI. A topography of immunotherapies against gastrointestinal malignancies. Panminerva Medica 2022; 64(1) doi: 10.23736/S0031-0808.21.04541-9
|
| 46 |
Shadi A. Esfahani, Li Ma, Shriya Krishna, Hua Ma, Shvan J. Raheem, Sergey Shuvaev, Nicholas J. Rotile, Jonah Weigand-Whittier, Avery T. Boice, Nicholas Borges, Constantina A. Treaba, Caitlin Deffler, Himashinie Diyabalanage, Valerie Humblet, David E. Sosnovik, Umar Mahmood, Pedram Heidari, Angela Shih, Ciprian Catana, Matthew R. Strickland, Samuel J. Klempner, Peter Caravan. Development of a fibrin-targeted theranostic for gastric cancer. Science Translational Medicine 2024; 16(777) doi: 10.1126/scitranslmed.adn7218
|
| 47 |
Minghui Zhou, Minfeng Ye, Jia Chen, Feng Tao. A case of recurrence following comprehensive treatment for advanced gastric cancer with HER-2 amplification. Asian Journal of Surgery 2024; 47(1): 630 doi: 10.1016/j.asjsur.2023.09.146
|
| 48 |
Cheng Zhang, Zuhua Chen, Xiaoyi Chong, Yang Chen, Zhenghang Wang, Ruoying Yu, Tingting Sun, Xiaoxi Chen, Yang Shao, Xiaotian Zhang, Jing Gao, Lin Shen. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies. Clinical and Translational Medicine 2020; 10(8) doi: 10.1002/ctm2.254
|
| 49 |
Cristina Díaz del Arco, Luis Ortega Medina, Lourdes Estrada Muñoz, Elena Molina Roldán, M. Ángeles Cerón Nieto, Soledad García Gómez de las Heras, M. Jesús Fernández Aceñero. Are Borrmann’s Types of Advanced Gastric Cancer Distinct Clinicopathological and Molecular Entities? A Western Study. Cancers 2021; 13(12): 3081 doi: 10.3390/cancers13123081
|
| 50 |
José Pedro Cerón-Carrasco, Horacio Pérez-Sánchez, José Zúñiga, Alberto Requena. Antibodies as Carrier Molecules: Encapsulating Anti-Inflammatory Drugs inside Herceptine. The Journal of Physical Chemistry B 2018; 122(7): 2064 doi: 10.1021/acs.jpcb.7b10749
|
| 51 |
Ritu Asnani, Padma K. Shetty, Vijith V. Shetty, Prakash Patil, Jayaprakash K. Shetty. Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach. Journal of Health and Allied Sciences NU 2024; doi: 10.1055/s-0044-1789609
|
| 52 |
Minsung Kim, Suhkneung Pyo, Chung Hyo Kang, Chong Ock Lee, Heung Kyoung Lee, Sang Un Choi, Chi Hoon Park, Ryan M. Teague. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLOS ONE 2018; 13(6): e0198347 doi: 10.1371/journal.pone.0198347
|
| 53 |
Jolanta Jedrzkiewicz, Deepika Sirohi, Nermin Uvejzovic, H. Evin Gulbahce. RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory. Modern Pathology 2022; 35(4): 549 doi: 10.1038/s41379-021-00933-4
|
| 54 |
Rita Nogueiras‐Álvarez, Inés Pérez Francisco. Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy. British Journal of Clinical Pharmacology 2024; doi: 10.1111/bcp.16181
|
| 55 |
Alessio Biagioni, Ileana Skalamera, Sara Peri, Nicola Schiavone, Fabio Cianchi, Elisa Giommoni, Lucia Magnelli, Laura Papucci. Update on gastric cancer treatments and gene therapies. Cancer and Metastasis Reviews 2019; 38(3): 537 doi: 10.1007/s10555-019-09803-7
|
| 56 |
Mumini Wemimo Rasheed, Afolayan Enoch Abiodun, Uchechukwu Brian Eziagu, Najeem Adedamola Idowu, Abdullahi Kabiru, Taiwo Adeyemi Adegboye, Waheed Akanni Oluogun, Adekunle Adebayo Ayoade. Clinicopathological and Immunohistochemical Characterization of Gastrointestinal Stromal Tumour at Four Tertiary Health Centers in Nigeria Using CD117, DOG1, and Human Epidermal Growth Factor Receptor-2 Biomarkers. Annals of African Medicine 2023; 22(4): 501 doi: 10.4103/aam.aam_180_22
|
| 57 |
Shota Fukuoka, Yoshikatsu Koga, Mayumi Yamauchi, Shigehiro Koganemaru, Masahiro Yasunaga, Kohei Shitara, Toshihiko Doi, Takayuki Yoshino, Toshio Kuronita, Brian Elenbaas, Pamela Wahra, Hong Zhang, Lindsey Crowley, Molly H. Jenkins, Anderson Clark, Takashi Kojima. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-40612-9
|
| 58 |
Adrian Constantin, Roxana Constantin, Florin Achim, Bogdan Socea, Dragos Predescu. Pregnancy and Gastric Cancer: A Narrative Review. Diagnostics 2023; 13(11): 1909 doi: 10.3390/diagnostics13111909
|
| 59 |
Anzhelika Vorobyeva, Kristina Westerlund, Bogdan Mitran, Mohamed Altai, Sara Rinne, Jens Sörensen, Anna Orlova, Vladimir Tolmachev, Amelie Eriksson Karlström. Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-27886-0
|
| 60 |
Xiao Guan, Na Lu, Jianping Zhang. Evaluation of Epidermal Growth Factor Receptor 2 Status in Gastric Cancer by Computer Tomography-Based Deep Learning Radiomics Nomogram. SSRN Electronic Journal 2022; doi: 10.2139/ssrn.4055520
|
| 61 |
Lidia Gago, Francisco Quiñonero, Gloria Perazzoli, Consolación Melguizo, Jose Prados, Raul Ortiz, Laura Cabeza. Nanomedicine and Hyperthermia for the Treatment of Gastrointestinal Cancer: A Systematic Review. Pharmaceutics 2023; 15(7): 1958 doi: 10.3390/pharmaceutics15071958
|
| 62 |
Magdalena Skórzewska, Katarzyna Gęca, Wojciech P. Polkowski. A Clinical Viewpoint on the Use of Targeted Therapy in Advanced Gastric Cancer. Cancers 2023; 15(22): 5490 doi: 10.3390/cancers15225490
|
| 63 |
Simona Costache, Rebecca de Havilland, Sofia Diaz McLynn, Maria Sajin, Adelina Baltan, Sarah Wedden, Corrado D’Arrigo. Implementing an On-Slide Molecular Classification of Gastric Cancer: A Tissue Microarray Study. Cancers 2023; 16(1): 55 doi: 10.3390/cancers16010055
|
| 64 |
Ricardo Oliveros Wilches, Jonathan Armando Sierra Prieto, Carlos Bonilla González, Jorge Andrés Mesa López de Mesa. La importancia de la determinación del HER 2 en el cáncer gástrico avanzado: a propósito de un caso clínico. Revista colombiana de Gastroenterología 2021; 36(Supl. 1): 2 doi: 10.22516/25007440.503
|
| 65 |
Hongsik Kim, Seung-Myoung Son, Chang Gok Woo, Ok-Jun Lee, Dae Hoon Kim, Hyo Yung Yun, Jieun Yun, Hee Kyung Kim, Yaewon Yang, Hye Sook Han. Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6035-0
|
| 66 |
D. L. Rotin, O. V. Paklina, I. O. Tin’kova, D. N. Grekov, G. R. Setdikova. CURRENT POINT OF VIEW ON PROGNOSTIC AND PREDICTIVE ROLES AND PRACTICAL APPLICATION OF HER2 RECEPTOR’S DETECTION. LITERATURE REVIEW. Russian Journal of Biotherapy 2020; 19(2): 6 doi: 10.17650/1726-9784-2019-19-2-6-12
|
| 67 |
Alexander Gudkov, Valery Shirokorad, Kirill Kashintsev, Dmitriy Sokov, Daniil Nikitin, Andrey Anisenko, Nicolas Borisov, Marina Sekacheva, Nurshat Gaifullin, Andrew Garazha, Maria Suntsova, Elena Koroleva, Anton Buzdin, Maksim Sorokin. Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer. Frontiers in Molecular Biosciences 2022; 9 doi: 10.3389/fmolb.2022.753318
|
| 68 |
Natalia Magdalena Chrzanowska, Janusz Kowalewski, Marzena Anna Lewandowska. Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors. Molecules 2020; 25(8): 1864 doi: 10.3390/molecules25081864
|
| 69 |
Esmeralda Celia Marginean. Gastric Cancer: Applicability and Feasibility of Molecular and Histological Classification in Clinical Practice. Journal of Medical and Radiation Oncology 2021; 1(2): 8 doi: 10.53011/JMRO.2021.02.02
|
| 70 |
Hayemin Lee, Han Hong Lee, Chae Youn Lim, Junhyun Lee. The utility of high-mobility group A2 overexpression for predicting the prognosis of gastric cancer patients and its contribution to poor prognosis via chemoresistance and the propensity for the occurrence of carcinomatosis peritonei. Surgery 2021; 169(5): 1213 doi: 10.1016/j.surg.2020.11.020
|
| 71 |
Christopher G. Sakellis, Heather A. Jacene, Annick D. Van den Abbeele. Nuclear Oncology. 2022; : 1 doi: 10.1007/978-3-319-26067-9_14-2
|
| 72 |
Xinyue Zhang, Jie Yao, Kai Guo, Hu Huang, Siyuan Huai, Rui Ye, Baolong Niu, Tiannan Ji, Weidong Han, Jianxiong Li. The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin. Oncotarget 2018; 9(2): 2105 doi: 10.18632/oncotarget.23249
|
| 73 |
Yuki Hirase, Takaaki Arigami, Yota Kawasaki, Daisuke Matsushita, Masataka Shimonosono, Yusuke Tsuruda, Ken Sasaki, Yoichi Yamasaki, Takahiko Hagihara, Hidetoshi Noma, Michiyo Higashi, Hiroshi Kurahara, Takao Ohtsuka. Successful subtotal gastrectomy and hepatectomy for HER2-positive gastric cancer with liver metastasis after trastuzumab-based chemotherapy: a case report. Surgical Case Reports 2024; 10(1) doi: 10.1186/s40792-024-01852-7
|
| 74 |
|
| 75 |
Antonio Ieni, Roberta Cardia, Cristina Pizzimenti, Pio Zeppa, Giovanni Tuccari. HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different Methodologies. Journal of Personalized Medicine 2020; 10(1): 10 doi: 10.3390/jpm10010010
|
| 76 |
Mariia Ivanova, Elham Sajjadi, Lorenzo Zattoni, Nicola Fusco. Hereditary Gastric and Breast Cancer Syndrome. 2023; : 149 doi: 10.1007/978-3-031-21317-5_10
|
| 77 |
A. Babkoff, A. Zick, A. Hubert, P. Tarantino, A. Grinshpun. Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future. ESMO Gastrointestinal Oncology 2024; 3: 100032 doi: 10.1016/j.esmogo.2023.100032
|
| 78 |
Animesh Saurabh, Vandana Raphael, Biswajit Dey, Caleb Harris, Vikas Jagtap, Umesh Das. Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma. Indian Journal of Surgical Oncology 2021; 12(S1): 144 doi: 10.1007/s13193-020-01245-w
|
| 79 |
Guodong Liang, Yuehan Ma, Ping Deng, Shufeng Li, Chunyan He, Haihang He, Hairui Liu, Yunda Fan, Ze Li. Role of cell-based therapies in digestive disorders: Obstacles and opportunities. Regenerative Therapy 2025; 29: 1 doi: 10.1016/j.reth.2025.02.009
|
| 80 |
Abdi İbrahim Sönmez, Alper Sevinc, İbrahim Sarı, İrfan Koruk, Musa Aydınlı, Serdar Öztuzcu, Beyhan Cengiz. Evaluation of Her2 Positivity in Gastric Cancer Using Two Different Methods: A Prospective Study. Genel Tıp Dergisi 2025; 35(1): 21 doi: 10.54005/geneltip.1441657
|
| 81 |
Jae Seung Soh, Hyun Lim, Ho Suk Kang, Jong Hyeok Kim, Kab Choong Kim. Does the discrepancy in histologic differentiation between a forceps biopsy and an endoscopic specimen necessitate additional surgery in early gastric cancer?. World Journal of Gastrointestinal Oncology 2017; 9(8): 319-326 doi: 10.4251/wjgo.v9.i8.319
|
| 82 |
D. S. Romanyuk, A. M. Pilunov, G. A. Efimov, A. V. Bogolyubova, E. N. Parovichnikova. Minor histocompatibility antigens represented in HLA-A*02:01 and their search strategies. Oncohematology 2023; 18(3): 115 doi: 10.17650/1818-8346-2023-18-3-115-124
|
| 83 |
Cristina Díaz del Arco, María Jesús Fernández Aceñero, Luis Ortega Medina. Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration. International Journal of Molecular Sciences 2024; 25(5): 2649 doi: 10.3390/ijms25052649
|
| 84 |
Guixia Pan, Danni Li, Xiao Li, Ye Peng, Tao Wang, Changjing Zuo. SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using 125I-Herceptin. Biochemical and Biophysical Research Communications 2018; 504(4): 765 doi: 10.1016/j.bbrc.2018.08.201
|
| 85 |
José Pedro Santos, Joana Figueiredo, José Carlos Machado. Gastric Cancer Genetics and Its Implications for Diagnosis, Prognosis, and Treatment of the Disease. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2024; 24(2): 103 doi: 10.7704/kjhugr.2024.0018
|
| 86 |
Yinxing Zhu, Xuedan Zhu, Xiaowei Wei, Cuiju Tang, Wenwen Zhang. HER2-targeted therapies in gastric cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2021; 1876(1): 188549 doi: 10.1016/j.bbcan.2021.188549
|
| 87 |
Fabiana G. Curea, Mohamed Hebbar, Silvia M. Ilie, Xenia E. Bacinschi, Oana G. Trifanescu, Inga Botnariuc, Rodica M. Anghel. Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma. Cancer Biotherapy and Radiopharmaceuticals 2017; 32(10): 351 doi: 10.1089/cbr.2017.2249
|
| 88 |
Weiling Li, Xiaoling Zhang, Yunyi Du, Ying Zhang, Jing Lu, Wenqing Hu, Jun Zhao. HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives. Biomarker Research 2022; 10(1) doi: 10.1186/s40364-022-00416-x
|
| 89 |
Leila Moradi, Fatemeh Tajik, Leili Saeednejad Zanjani, Mahshid Panahi, Elmira Gheytanchi, Zahra Sadat Biabanaki, Golnaz Ensieh Kazemi-Sefat, Farideh Hashemi, Masoumeh Dehghan Manshadi, Zahra Madjd. Clinical significance of CD166 and HER-2 in different types of gastric cancer. Clinical and Translational Oncology 2023; 26(3): 664 doi: 10.1007/s12094-023-03297-0
|
| 90 |
Héber S. C. Ribeiro, Jacqueline N. Menezes, Wilson L. da Costa, Victor Hugo F. de Jesus, Alessandro L. Diniz, André L. Godoy, Igor Correia de Farias, Silvio M. Torres, Tatiane Neotti, Celso A. L. Mello, Maria Dirlei F. S. Begnami, Emmanuel Dias‐Neto, Rachel P. Riechelmann, Felipe José Fernandez Coimbra. PD‐L1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy. Journal of Surgical Oncology 2022; 126(1): 150 doi: 10.1002/jso.26929
|
| 91 |
Anna Pous, Lucía Notario, Cinta Hierro, Laura Layos, Cristina Bugés. HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. International Journal of Molecular Sciences 2023; 24(14): 11403 doi: 10.3390/ijms241411403
|
| 92 |
Natasha Rekhtman, Marina K Baine, Justin A. Bishop. Quick Reference Handbook for Surgical Pathologists. 2019; : 59 doi: 10.1007/978-3-319-97508-5_4
|
| 93 |
Damaris-Cristina Gheorghe, Raluca-Ioana Stefan-Van Staden, Ruxandra-Maria Ilie-Mihai, Paula Sfirloaga. Nanoplatform-based analysis for the detection of HER3 and HER4 for gastric cancer diagnosis. Nanotechnology 2023; 34(34): 345101 doi: 10.1088/1361-6528/acd9d3
|
| 94 |
Bharat Jasani, Ralf Huss, Clive R. Taylor. Precision Cancer Medicine. 2021; : 43 doi: 10.1007/978-3-030-84087-7_5
|
| 95 |
Hiroaki Ikushima, Kiyoshi Yamaguchi, Yoichi Furukawa, Seiya Imoto, Hirotomo Koda, Takuro Mizukami, Teppei Morikawa, Keita Uchino. Transdifferentiation of cervical squamous cell carcinoma with ERBB2 amplification to adenocarcinoma: whole genome sequence analysis and successful control by anti-HER2 therapy. BJC Reports 2023; 1(1) doi: 10.1038/s44276-023-00015-9
|
| 96 |
Angeliki Andrikopoulou, Flora Zagouri, Kallirroi Goula, Dimitrios Haidopoulos, Nikolaos Thomakos, Anna Svarna, Meletios-Athanasios Dimopoulos, Michalis Liontos. Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignancies. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-13226-1
|
| 97 |
Ryan Varghese, Niraja Soman, Jainam Karsiya, Nimesh Bafna, Shona Nag. Fam-trastuzumab deruxtecan-nxki (Enhertu®): A narrative drug review. Cancer Research, Statistics, and Treatment 2022; 5(4): 701 doi: 10.4103/crst.crst_302_22
|
| 98 |
Jingying Yue, Shuai Shao, Jie Zhou, Wenting Luo, Yanling Xu, Qinbin Zhang, Jing Jiang, Marie M Zhu. A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function. Investigational New Drugs 2024; 42(1): 106 doi: 10.1007/s10637-024-01417-3
|
| 99 |
Matthew W. Rosenbaum, Raul S. Gonzalez. Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies. Seminars in Diagnostic Pathology 2022; 39(1): 48 doi: 10.1053/j.semdp.2021.10.003
|
| 100 |
Ravi M Swami, Binal N Patel, Rachana Lakhe, Ravindra Nimbargi. Study of prognostic indicators and Her2neu expression in gastric adenocarcinomas – A tertiary care centre study. Indian Journal of Pathology and Oncology 2021; 8(1): 104 doi: 10.18231/j.ijpo.2021.021
|
| 101 |
Jiankun Liu, Tienian Zhu, Ruijing Zhao, Wenjun Ren, Fei Zhao, Jingpu Liu. Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer. Gastric Cancer 2024; 27(3): 495 doi: 10.1007/s10120-024-01478-6
|
| 102 |
Alyssa C. Bujnak, Samantha A. Solaru, Krishnansu Tewari. Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics. Gynecologic Oncology 2025; 195: 180 doi: 10.1016/j.ygyno.2025.03.013
|
| 103 |
R Cahyanur, AP Utari, N Rahadiani. Cyclin D1 Expression, Clinicopathological Characteristics, and 2-Year Survival Rate of Gastric Cancer in Cipto Mangunkusumo General Hospital. Nigerian Journal of Clinical Practice 2023; 26(8): 1057 doi: 10.4103/njcp.njcp_222_22
|
| 104 |
Siao-Syun Guan, Cheng-Tien Wu, Chen-Yuan Chiu, Tsai-Yueh Luo, Jeng-Yih Wu, Tse-Zung Liao, Shing-Hwa Liu. Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo. Journal of Translational Medicine 2018; 16(1) doi: 10.1186/s12967-018-1550-3
|
| 105 |
Zheng-Yan Yang, Yi-Wei Zhao, Jing-Rui Xue, Ran Guo, Zhi Zhao, Han-Di Liu, Zhi-Guang Ren, Ming Shi. Thioridazine reverses trastuzumab resistance in gastric cancer by inhibiting S-phase kinase associated protein 2-mediated aerobic glycolysis. World Journal of Gastroenterology 2023; 29(45): 5974-5987 doi: 10.3748/wjg.v29.i45.5974
Abstract(621) |
Core Tip(602) |
Full Article(HTML)(2038)
|
Full Article with Cover (PDF)-11392K(114)
|
Full Article (Word)-4523K(32)
|
Audio-497K(5)
|
Peer-Review Report-228K(71)
|
Answering Reviewers-122K(72)
|
Full Article (PDF)-7471K(147)
|
Full Article (XML)-144K(73)
|
Times Cited (1)
|
Total Visits (6127)
|
Open
|
| 106 |
Maitry Goel, Vibha Gupta. Innovative Advancements in Biotechnology. Advances in Science, Technology & Innovation 2025; : 211 doi: 10.1007/978-3-031-80189-1_16
|
| 107 |
Hua Ye, Xuyu Chai, Xiaoyu Wang, Qi Zheng, Dingcheng Zheng, Feng Wu, Cheng Zheng, Ping Chen. Autophagy flux inhibition augments gastric cancer resistance to the anti-human epidermal growth factor receptor 2 antibody trastuzumab. Oncology Letters 2018; doi: 10.3892/ol.2018.7891
|
| 108 |
Yuli Wang, Yuan Fang, Fanchen Zhao, Jiefei Gu, Xiang Lv, Rongzhong Xu, Bo Zhang, Zhihong Fang, Yan Li. Identification of GGT5 as a Novel Prognostic Biomarker for Gastric Cancer and its Correlation With Immune Cell Infiltration. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.810292
|
| 109 |
Vincenzo Canzonieri, Federica Rao, Tiziana Perin, Lara Alessandrini, Angela Buonadonna, Giulio Bertola, Claudio Belluco, Renato Cannizzaro, Antonino De Paoli, Antonio Giordano. Gastric Cancer In The Precision Medicine Era. Current Clinical Pathology 2019; : 83 doi: 10.1007/978-3-030-04861-7_5
|
| 110 |
K. A. Oganyan, A. A. Musaelyan, S. V. Lapin, T. V. Kupenskaya, A. A. Sveсhkova, M. A. Belyaev, A. A. Zakharenko, S. V. Orlov. Molecular markers as predictors of response to perioperative chemotherapy in locally advanced gastric cancer. Advances in Molecular Oncology 2023; 10(1): 40 doi: 10.17650/2313-805X-2023-10-1-40-48
|
| 111 |
Guangjian Yang, Linyan Tian, Yan Wang. Hyperprogressive disease induced by PD-1 inhibitor monotherapy in lung adenocarcinoma with HER2 exon 20 insertion: report of two cases and review of literature. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-01749-3
|
| 112 |
Kun Fan, Jiwen Wang, Sheng Shen, Xiaojian Ni, Zijun Gong, Bohao Zheng, Wentao Sun, Tao Suo, Han liu, Xiaoling Ni, Houbao Liu. ERBB2 S310F mutation independently activates PI3K/AKT and MAPK pathways through homodimers to contribute gallbladder carcinoma growth. Medical Oncology 2022; 39(6) doi: 10.1007/s12032-021-01568-w
|
| 113 |
Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani, Angelica Petrillo. Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. Gastrointestinal Disorders 2020; 3(1): 1 doi: 10.3390/gidisord3010001
|
| 114 |
Mohammad K. Mohammad, Guoli Chen. Practical Oncologic Molecular Pathology. 2021; : 171 doi: 10.1007/978-3-030-73227-1_8
|
| 115 |
Roberto Carmagnani Pestana, Shiraj Sen, Brian P. Hobbs, David S. Hong. Histology-agnostic drug development — considering issues beyond the tissue. Nature Reviews Clinical Oncology 2020; 17(9): 555 doi: 10.1038/s41571-020-0384-0
|
| 116 |
Bagher Larijani, Parisa Goodarzi, Motahareh Sheikh Hosseini, Solmaz M. Nejad, Sepideh Alavi-Moghadam, Masoumeh Sarvari, Mina Abedi, Maryam Arabi, Fakher Rahim, Najmeh Foroughi Heravani, Mahdieh Hadavandkhani, Moloud Payab. Genomics, Proteomics, and Metabolomics. Stem Cell Biology and Regenerative Medicine 2019; : 141 doi: 10.1007/978-3-030-27727-7_8
|
| 117 |
Ximena Baez-Navarro, Floris H. Groenendijk, Lindsey Oudijk, Jan von der Thüsen, Nicola Fusco, Giuseppe Curigliano, Carolien H.M. van Deurzen. HER2-low across solid tumours: different incidences and definitions. Pathology 2025; doi: 10.1016/j.pathol.2025.02.003
|
| 118 |
Taylor A. Johnson, Dinender K. Singla. Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. Canadian Journal of Physiology and Pharmacology 2018; 96(7): 647 doi: 10.1139/cjpp-2018-0005
|
| 119 |
Demei Chen, Rui Zhou, Bo Li. Preoperative Prediction of Her-2 and Ki-67 Status in Gastric Cancer Using 18F-FDG PET/CT Radiomics Features of Visceral Adipose Tissue. British Journal of Hospital Medicine 2024; : 1 doi: 10.12968/hmed.2024.0350
|
| 120 |
Niraj Neupane, Sangharsha Thapa, Abhinav Bhattarai, Kriti Ahuja, Ilana Schlam, Abhenil Mittal, Sara M. Tolaney, Paolo Tarantino. Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan. Current Oncology Reports 2023; 25(12): 1467 doi: 10.1007/s11912-023-01469-3
|
| 121 |
Hye Ryeon Kim, Soomin Ahn, Hyunji Jo, Hongsik Kim, Joohyun Hong, Jeeyun Lee, Ho-Yeong Lim, Won Ki Kang, Seung Tae Kim. The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.792340
|
| 122 |
Marianna J. Bledsoe, William E. Grizzle. The Use of Human Tissues for Research: What Investigators Need to Know. Alternatives to Laboratory Animals 2022; 50(4): 265 doi: 10.1177/02611929221107933
|
| 123 |
Shin Nishio. Current status and molecular biology of human papillomavirus‐independent gastric‐type adenocarcinoma of the cervix. Journal of Obstetrics and Gynaecology Research 2023; 49(4): 1106 doi: 10.1111/jog.15578
|
| 124 |
Qi Xu, Xiaoqing Xu, Haimeng Tang, Junrong Yan, Jingjing Li, Hua Bao, Xue Wu, Yang Shao, Cong Luo, Haimin Wen, Jianying Jin, Jieer Ying. Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy. Oncogenesis 2023; 12(1) doi: 10.1038/s41389-023-00466-2
|
| 125 |
Qi Zhang, Zimu Zhang, Meiyu Peng, Shuyu Fu, Zhenyi Xue, Rongxin Zhang. CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside. OncoImmunology 2016; 5(12): e1251539 doi: 10.1080/2162402X.2016.1251539
|
| 126 |
Hiroyuki Kuwano, Takehiko Yokobori, Tatsuya Miyazaki, Makoto Sohda, Tomonori Yoshida, Yoko Azuma, Hironori Tatsuki, Yasunari Ubukata, Nobuhiro Nakazawa, Kengo Kuriyama, Akihiko Sano, Makoto Sakai, Hiroomi Ogawa, Hiroshi Saeki, Ken Shirabe. Field carcinogenesis and biological significance of the potential of the bystander effect: carcinogenesis, therapeutic response, and tissue regeneration. Surgery Today 2023; 53(5): 545 doi: 10.1007/s00595-022-02524-5
|
| 127 |
Soo-Yeon Hwang, Seojeong Park, Hyunji Jo, Seung Hee Seo, Kyung-Hwa Jeon, Seojeong Kim, Ah-Reum Jung, Chanju Song, Misun Ahn, Soo Yeon Kwak, Hwa-Jong Lee, Motonari Uesugi, Younghwa Na, Youngjoo Kwon. Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers. Journal of Advanced Research 2023; 47: 173 doi: 10.1016/j.jare.2022.08.003
|
| 128 |
Lin Shen, Yanqiao Zhang, Ziyu Li, Xiaotian Zhang, Xiangyu Gao, Bo Liu, Yusheng Wang, Yi Ba, Ning Li, Ruixing Zhang, Jingdong Zhang, Ye Chen, Jian Chen, Mingzhu Huang, Yang Fu, Mulin Liu, Zheng Liu, Jun Zhao, Wei Li, Jia Wei, Changzheng Li, Nong Xu, Zengqing Guo, Bangwei Cao, Lian Liu, Peng Nie, Lixin Wan, Lili Sheng, Zhenyang Liu, Yifu He, Kangsheng Gu, Guowu Wu, Weibo Wang, Futong Zhang, Wensheng Qiu, Jun Guo, Jieer Ying, Hongming Pan, Huiting Xu, Yuan Yuan, Yuansong Bai, Zhenghua Wang, Jiye Xu, Xuehong Zhao, Hao Liu, Xizhi Zhang, Wenxiang Dai, Hongyan Xu, Ming Liu, Lin Xie, Yong Tang, Jianying Jin, Xiujuan Qu, Xuefeng Fang, Mingwei Huang, Hao Chen, Zhendong Zheng, Ying Wang, Daqing Wang, Xiaoqin Li, Guohua Yu, Haiyan Liu, Yongjian Zhou, Diansheng Zhong, Shan Zeng, Mafei Kang, Meiqing Wang, Yong Gao, Wenxin Li, Zejun Wang, Minghui Zhang, Jinghua Zhang, Qingshan Li, Shujuan Sun, Aimin Zang, Lizhu Lin, Ming Xie, Zhixiang Zhuang, Tao Zhang, Zhifang Yao, Dongmei Lu, Wei Liu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Jiajia Zhang, Xiangji Ying, Drew M. Pardoll, Jiafu Ji. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nature Medicine 2025; doi: 10.1038/s41591-024-03450-4
|
| 129 |
Warisha Kanwal, Kaneez Narjis, Sarah Musani, Fnu Nancy, Laiba Qureshi, Muhammad Mudasir, Rohma Naseem, Fnu Tooba, Juvairia Yousuf, Kanza Farhan, Hadiya Javed, Mohammed Mahmmoud Fadelallah Eljack. Exploring Zanidatamab’s efficacy across HER2-positive Malignancies: a narrative review. BMC Cancer 2025; 25(1) doi: 10.1186/s12885-025-13749-1
|
| 130 |
Daniel V T Catenacci, Yoon-Koo Kang, Haeseong Park, Hope E Uronis, Keun-Wook Lee, Matthew C H Ng, Peter C Enzinger, Se Hoon Park, Philip J Gold, Jill Lacy, Howard S Hochster, Sang Cheul Oh, Yeul Hong Kim, Kristen A Marrone, Ronan J Kelly, Rosalyn A Juergens, Jong Gwang Kim, Johanna C Bendell, Thierry Alcindor, Sun Jin Sym, Eun-Kee Song, Cheng Ean Chee, Yee Chao, Sunnie Kim, A Craig Lockhart, Keith L Knutson, Jennifer Yen, Aleksandra Franovic, Jeffrey L Nordstrom, Daner Li, Jon Wigginton, Jan K Davidson-Moncada, Minori Koshiji Rosales, Yung-Jue Bang. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial. The Lancet Oncology 2020; 21(8): 1066 doi: 10.1016/S1470-2045(20)30326-0
|
| 131 |
Yuan-yuan Pei, Jian Ran, Lijuan Wen, Xiaoyi Liu, Li Xiang, Weiqiang Liu, Fengxiang Wei. Up-regulated GRB7 protein in gastric cancer cells correlates with clinical properties and increases proliferation and stem cell properties. Frontiers in Oncology 2023; 12 doi: 10.3389/fonc.2022.1054976
|
| 132 |
Mika K. Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, Takuro Nakamura, Miyuki Yanaka, Tomohiro Tanaka, Yukinari Kato. Antitumor Activities of a Humanized Cancer-Specific Anti-HER2 Monoclonal Antibody, humH2Mab-250 in Human Breast Cancer Xenografts. International Journal of Molecular Sciences 2025; 26(3): 1079 doi: 10.3390/ijms26031079
|
| 133 |
Soma Kobayashi, Joel H Saltz, Vincent W Yang. State of machine and deep learning in histopathological applications in digestive diseases. World Journal of Gastroenterology 2021; 27(20): 2545-2575 doi: 10.3748/wjg.v27.i20.2545
|
| 134 |
Pengfei Ji, Tingting Chen, Chao Li, Jinyuan Zhang, Xiao Li, Hong Zhu. Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers. Critical Reviews in Oncology/Hematology 2025; 206: 104586 doi: 10.1016/j.critrevonc.2024.104586
|
| 135 |
·亚尔买买提 伊力亚斯. Advances in Imaging Studies of Human Epidermal Growth Factor Receptor 2 in Gastric Cancer. Advances in Clinical Medicine 2023; 13(09): 14687 doi: 10.12677/ACM.2023.1392053
|
| 136 |
Arghya Kusum Dhar, Sidhartha S. Kar. Biosimilars for Cancer Treatment. 2024; : 121 doi: 10.1007/978-981-97-3001-8_7
|
| 137 |
De-Ping Wang, Rong Zhao, Yue-Hong Qi, Jing Shen, Jia-Yi Hou, Mei-Yue Wang, Xiao-Gang Bi, Xiao-Qing Guo, Ji-Min Cao, Reza Izadpanah. High Expression of Interleukin-2 Receptor Subunit Gamma Reveals Poor Prognosis in Human Gastric Cancer. Journal of Oncology 2021; 2021: 1 doi: 10.1155/2021/6670834
|
| 138 |
Bihong Xu, Chunyu Huang, Xianzi Yang, Xiangzhao Li, Liang Li, Yanqing Ding. Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer. Oncology Letters 2018; doi: 10.3892/ol.2018.7992
|
| 139 |
Hersh A. Ham-Karim, Henry Okuchukwu Ebili, Kirsty Manger, Wakkas Fadhil, Narmeen S. Ahmad, Susan D. Richman, Mohammad Ilyas. Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer. Molecular Diagnosis & Therapy 2019; 23(3): 383 doi: 10.1007/s40291-019-00388-z
|
| 140 |
Guanghua Li, Zhihao Zhou, Zhixiong Wang, Zhao Wang. Assessing Epstein–Barr virus in gastric cancer: clinicopathological features and prognostic implications. Infectious Agents and Cancer 2023; 18(1) doi: 10.1186/s13027-023-00489-9
|
| 141 |
Tjalling Bosse, Sigurd Lax, Nadeem Abu-Rustum, Xavier Matias-Guiu. The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology 2021; 40(Supplement 1): S102 doi: 10.1097/PGP.0000000000000755
|
| 142 |
Sangjoon Choi, Sujin Park, Hyunjin Kim, So Young Kang, Soomin Ahn, Kyoung-Mee Kim. Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches. Biomedicines 2022; 10(3): 543 doi: 10.3390/biomedicines10030543
|
| 143 |
Hsiao-Hsuan Wan, Haochen Zhu, Chao-Ching Chiang, Jian-Sian Li, Fan Ren, Cheng-Tse Tsai, Yu-Te Liao, Dan Neal, Josephine F. Esquivel-Upshaw, Stephen J. Pearton. High sensitivity saliva-based biosensor in detection of breast cancer biomarkers: HER2 and CA15-3. Journal of Vacuum Science & Technology B 2024; 42(2) doi: 10.1116/6.0003370
|
| 144 |
Simona Costache, Adelina Baltan , Sofia Diaz McLinn , Mattia Pegoraro , Rebecca de Havilland , Matthew Porter , Ana Lerga , Teresa Thomas , Alina Elena Chefani . Implementing an integrated molecular classification for gastric cancer from endoscopic biopsies using on-slide tests. Romanian Journal of Morphology and Embryology 2024; 65(2): 257 doi: 10.47162/RJME.65.2.12
|
| 145 |
Mengying Xu, Song Liu, Xiangmei Qiao, Lin Li, Changfeng Ji, Zhengyang Zhou. Clinicopathological features and CT findings of papillary gastric adenocarcinoma. Abdominal Radiology 2022; 47(11): 3698 doi: 10.1007/s00261-022-03635-w
|
| 146 |
Zhu Zeng, Qing Zhu. Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1382183
|
| 147 |
Mona Y.Y. Abd-Allah, Ramy Ahmed Abdel-Salam, Sherine Refat. Immunohistochemical expression of FOXP3 in gastric carcinoma; its relation to Ki-67 proliferation marker, HER2/neu expression, and other clinicopathological parameters. Journal of Immunoassay and Immunochemistry 2022; 43(2) doi: 10.1080/15321819.2021.1959341
|
| 148 |
Dominika Bębnowska, Ewelina Grywalska, Paulina Niedźwiedzka-Rystwej, Barbara Sosnowska-Pasiarska, Jolanta Smok-Kalwat, Marcin Pasiarski, Stanisław Góźdź, Jacek Roliński, Wojciech Polkowski. CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer. Journal of Clinical Medicine 2020; 9(6): 1894 doi: 10.3390/jcm9061894
|
| 149 |
Tajul Islam Mamun, Sabrina Younus, Md. Hashibur Rahman. Gastric cancer—Epidemiology, modifiable and non-modifiable risk factors, challenges and opportunities: An updated review. Cancer Treatment and Research Communications 2024; 41: 100845 doi: 10.1016/j.ctarc.2024.100845
|
| 150 |
Suresh Kumar Bondili, Ravindra Nandhana, Vanita Noronha, Swayamprabha Pawar, Nandini Menon, Omshree Shetty, Anuradha Chougule, Abhishek Mahajan, Rajiv Kumar, Vijay M. Patil, Amit Joshi, Kumar Prabhash. HER2 alterations in non-small-cell lung cancer – Druggable or undruggable?. Cancer Research, Statistics, and Treatment 2021; 4(2): 374 doi: 10.4103/crst.crst_81_21
|
| 151 |
Timil H. Patel, Michael Cecchini. Targeted Therapies in Advanced Gastric Cancer. Current Treatment Options in Oncology 2020; 21(9) doi: 10.1007/s11864-020-00774-4
|
| 152 |
Xiaojing Jiang, Tianyue Li, Jianfang Wang, Zhaoqi Zhang, Xiaolin Chen, Jingmian Zhang, Xinming Zhao. Noninvasive Assessment of HER2 Expression Status in Gastric Cancer Using 18F-FDG Positron Emission Tomography/Computed Tomography-Based Radiomics: A Pilot Study. Cancer Biotherapy and Radiopharmaceuticals 2024; 39(3): 169 doi: 10.1089/cbr.2023.0162
|
| 153 |
Noreen McBrearty, Devika Bahal, Suso Platero. Fast-tracking drug development with biomarkers and companion diagnostics. Journal of Cancer Metastasis and Treatment 2024; doi: 10.20517/2394-4722.2023.134
|
| 154 |
Xinyi Zhou. Current status of CAR-T cells in the treatment of malignant solid tumors. 7TH INTERNATIONAL CONFERENCE ON MATHEMATICS: PURE, APPLIED AND COMPUTATION: Mathematics of Quantum Computing 2022; 2641: 020028 doi: 10.1063/5.0111898
|
| 155 |
Shivanshu Mishra, Pharyanshu Kachhawa, Amber Kumar Jain, Rajiv Ranjan Thakur, Nidhi Chaturvedi. High sensitivity label-free detection of HER2 using an Al–GaN/GaN high electron mobility transistor-based biosensor. Lab on a Chip 2022; 22(21): 4129 doi: 10.1039/D2LC00349J
|
| 156 |
Melin GECER, Nur BÜYÜKPINARBAŞILI, Seval TURNA, Mehmet BEŞİROĞLU, Zuhal GUCIN. Comparison of human epidermal growth factor receptor 2 and cancer stem cell markers like CD44 and CD133 expressions with clinicopathological parameters in gastric cancer. The European Research Journal 2023; 9(5): 1015 doi: 10.18621/eurj.1296567
|
| 157 |
Liang Wang, Congxiu Miao, Yuan He, Hanglong Li, Shasha Zhang, Keyan Li, Huimin Liu, Wushuang Li, Jiangman Zhao, Yue Xu, Hui Tang, Qiang Zhao, Raluca-Ioana Stefan-Van Staden. The Influence of Heavy Metals on Gastric Tumorigenesis. Journal of Oncology 2022; 2022: 1 doi: 10.1155/2022/6425133
|
| 158 |
Yi-Xiang Wu, Xiao-Yu Zhou, Jian-Qi Wang, Gao-Min Chen, Jin-Xu Chen, Rong-Chang Wang, Jiong-Qiang Huang, Jing-Song Chen. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer. Immunotherapy 2023; 15(2): 101 doi: 10.2217/imt-2022-0080
|
| 159 |
|
| 160 |
Rachel E. Sexton, Mohammed Najeeb Al Hallak, Maria Diab, Asfar S. Azmi. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer and Metastasis Reviews 2020; 39(4): 1179 doi: 10.1007/s10555-020-09925-3
|
| 161 |
Fatemeh Amirmoezi, Bita Geramizadeh. Molecular Classification of Gastric Cancer With Emphasis on PDL-1 Expression: The First Report From Iran. Clinical Pathology 2022; 15 doi: 10.1177/2632010X221096378
|
| 162 |
Lin Cui, Xiuqing Wang, Dekai Zhang. TLRs as a Promise Target Along With Immune Checkpoint Against Gastric Cancer. Frontiers in Cell and Developmental Biology 2021; 8 doi: 10.3389/fcell.2020.611444
|
| 163 |
Christopher G. Sakellis, Heather A. Jacene, Annick D. Van den Abbeele. Nuclear Oncology. 2022; : 829 doi: 10.1007/978-3-031-05494-5_14
|
| 164 |
Serhat Sekmek, Irfan Karahan, Gokhan Ucar, Furkan Ceylan, Dogan Bayram, Ismet Seven, Hatice Bölek, Yüksel Ürün, Kadriye Bir Yücel, Ozan Yazici, Ahmet Kadioglu, Cengiz Karacin, Kubra Canaslan, Elif Atag, Serhat Demirer, Gokmen Umut Erdem, Yakup Ergun, Mehmetcan Atak, Baris Koksal, Merve Meryem Kiran, Duriye Ozer Turkay, Burak Civelek, Bulent Yalcin, Dogan Uncu. Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study. Clinical and Translational Oncology 2024; 26(8): 1878 doi: 10.1007/s12094-024-03410-x
|
| 165 |
Mengying Xu, Song Liu, Lin Li, Xiangmei Qiao, Changfeng Ji, Lingyu Tan, Zhengyang Zhou. Development and validation of multivariate models integrating preoperative clinicopathological and radiographic findings to predict HER2 status in gastric cancer. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-18433-z
|
| 166 |
Maryam Oroujeni, Hanna Tano, Anzhelika Vorobyeva, Yongsheng Liu, Olga Vorontsova, Tianqi Xu, Kristina Westerlund, Anna Orlova, Vladimir Tolmachev, Amelie Eriksson Karlström. Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts. Journal of Nuclear Medicine 2022; 63(7): 1046 doi: 10.2967/jnumed.121.262123
|
| 167 |
Rafid A. Abood, Saad Alomar, Sawsan S. Alharoon. A study of human epidermal growth factor receptor 2 overexpression by immunohistochemistry in patients with gastric adenocarcinoma. Journal of Public Health in Africa 2023; 14(9): 4 doi: 10.4081/jphia.2023.2721
|
| 168 |
Niki Christou, Sabrina Blondy, Valentin David, Mireille Verdier, Fabrice Lalloué, Marie-Odile Jauberteau, Muriel Mathonnet, Aurélie Perraud. Neurotensin pathway in digestive cancers and clinical applications: an overview. Cell Death & Disease 2020; 11(12) doi: 10.1038/s41419-020-03245-8
|
| 169 |
Anna D. Wagner, Florian Lordick, Heike I. Grabsch, Masanori Terashima, Mitsumi Terada, Takaki Yoshikawa, Narikazu Boku, Kozo Kataoka, Elizabeth C. Smyth, Murielle Mauer, Karin Haustermans, Markus H. Moehler. Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. European Journal of Cancer 2020; 124: 67 doi: 10.1016/j.ejca.2019.09.006
|
| 170 |
Cong Chen, Jing Han, Qifei He, Qian Yao, Xueying Wang, Zuofu Peng, Yu Sun, Jiafu Ji, Xiaofang Xing. Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer. British Journal of Cancer 2024; 131(9): 1463 doi: 10.1038/s41416-024-02835-z
|
| 171 |
Jill C. Rubinstein, Norman G. Nicolson, Nita Ahuja. Next-generation Sequencing in the Management of Gastric and Esophageal Cancers. Surgical Clinics of North America 2019; 99(3): 511 doi: 10.1016/j.suc.2019.02.005
|
| 172 |
Matteo Franchi, Roberta Tritto, Lorena Torroni, Chiara Reno, Carlo La Vecchia, Giovanni Corrao. Effectiveness and Healthcare Cost of Adding Trastuzumab to Standard Chemotherapy for First-Line Treatment of Metastatic Gastric Cancer: A Population-Based Cohort Study. Cancers 2020; 12(6): 1691 doi: 10.3390/cancers12061691
|
| 173 |
Ousman Mohammed, Solomon Tebeje Gizaw, Maria Degef. Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer. Health Science Reports 2024; 7(7) doi: 10.1002/hsr2.2261
|
| 174 |
Liyijing Shen, Yaoqing Li, Huizhen Huang, Zengxin Lu, Bo Chen. HER2 in Gastric Cancer: A Comprehensive Analysis Combining Meta-Analysis and DCE-MRI Radiomics. Cancer Control 2024; 31 doi: 10.1177/10732748241293699
|
| 175 |
Lauren Jones, David Cunningham, Naureen Starling. HER-2 directed therapies across gastrointestinal tract cancers – A new frontier. Cancer Treatment Reviews 2024; 129: 102789 doi: 10.1016/j.ctrv.2024.102789
|
| 176 |
Zhen-Hua Liu, Bo-Wen Zhu, Min Shi, Yu-Rong Qu, Xun-Jun He, Hong-Ling Yuan, Jie Ma, Wei Li, Dan-Dan Zhao, Zheng-Chuang Liu, Bao-Ming Wang, Chun-Yang Wang, Hou-Quan Tao, Tong-Hui Ma. Profiling of gene fusion involving targetable genes in Chinese gastric cancer. World Journal of Gastrointestinal Oncology 2022; 14(8): 1528-1539 doi: 10.4251/wjgo.v14.i8.1528
|
| 177 |
Qingqing Ding, Hui Chen, Bora Lim, Senthil Damodaran, Weiwei Chen, Debu Tripathy, Sarina Piha-Paul, Rajyalakshmi Luthra, Funda Meric-Bernstam, Aysegul A. Sahin. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Human Pathology 2019; 92: 32 doi: 10.1016/j.humpath.2019.07.006
|
| 178 |
Alessandro Agnarelli, Viviana Vella, Mark Samuels, Panagiotis Papanastasopoulos, Georgios Giamas. Incorporating Immunotherapy in the Management of Gastric Cancer: Molecular and Clinical Implications. Cancers 2022; 14(18): 4378 doi: 10.3390/cancers14184378
|
| 179 |
Kyoko Inagaki-Ohara. Gastric Leptin and Tumorigenesis: Beyond Obesity. International Journal of Molecular Sciences 2019; 20(11): 2622 doi: 10.3390/ijms20112622
|
| 180 |
Qiong Shao, Fang Wang, Yuxia Xu, Xu Zhang, Wenting Tang, Yanfen Feng, Yue Li, Anil K Verma. CDKL2 Is Associated with HER2 Status and Overall Survival in Gastric Cancer: Comparative Analysis of CDKL2 Protein Expression and Gene Copy Number. BioMed Research International 2020; 2020(1) doi: 10.1155/2020/1712723
|
| 181 |
Fatima M. Kipkeeva, Tatiana A. Muzaffarova, Maxim P. Nikulin, Pavel V. Apanovich, Alexander V. Karpukhin. PROMISING TARGETED THERAPIES GENES AND PROGNOSTIC BIOMARKERS OF GASTRIC CANCER. Annals of the Russian academy of medical sciences 2018; 73(4): 262 doi: 10.15690/vramn999
|
| 182 |
Yasushi Sato, Koichi Okamoto, Yutaka Kawano, Akinari Kasai, Tomoyuki Kawaguchi, Tamotsu Sagawa, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama. Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. Journal of Clinical Medicine 2023; 12(14): 4646 doi: 10.3390/jcm12144646
|
| 183 |
Shadi A. Esfahani, Cody Callahan, Nicholas J. Rotile, Pedram Heidari, Umar Mahmood, Peter D. Caravan, Aaron K. Grant, Yi-Fen Yen. Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer. Molecular Imaging and Biology 2022; 24(5): 769 doi: 10.1007/s11307-022-01727-z
|
| 184 |
Rachel L Stewart, Justin E Caron, Evin H Gulbahce, Rachel E Factor, Katherine B Geiersbach, Erinn Downs-Kelly. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Modern Pathology 2017; 30(11): 1561 doi: 10.1038/modpathol.2017.65
|
| 185 |
Ratih Kusumastuti, Yuji Kumagai, Seiichiro Ishihara, Atsushi Enomoto, Takashi Murakami, Motoaki Yasuda, Hisashi Haga. Mammaglobin 1 mediates progression of trastuzumab‐resistant breast cancer cells through regulation of cyclins and NF‐κB. FEBS Open Bio 2022; 12(10): 1797 doi: 10.1002/2211-5463.13468
|
| 186 |
Snigdha Sinha, Subhashish Das, S.M. Azeem Mohiyuddin . Evaluation of Cyclin D1 and Human Epidermal Growth Factor Receptor 2 Neu Protein Expression in Head and Neck Squamous Cell Carcinoma. Cureus 2023; doi: 10.7759/cureus.35526
|
| 187 |
Yoshihide Mitsuda, Ken Morita, Gengo Kashiwazaki, Junichi Taniguchi, Toshikazu Bando, Moeka Obara, Masahiro Hirata, Tatsuki R. Kataoka, Manabu Muto, Yasufumi Kaneda, Tatsutoshi Nakahata, Pu Paul Liu, Souichi Adachi, Hiroshi Sugiyama, Yasuhiko Kamikubo. RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-24969-w
|
| 188 |
Lulu Sun, John D. Pfeifer. Pitfalls in molecular diagnostics. Seminars in Diagnostic Pathology 2019; 36(5): 342 doi: 10.1053/j.semdp.2019.06.002
|
| 189 |
Xiaoyi Lin, Xin Lin, Yingzi Li, Yuchen Zhang, Jiali Lin, Guochun Zhang. Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study. International Journal of General Medicine 2021; : 8775 doi: 10.2147/IJGM.S338455
|
| 190 |
Nehal Gupta, Sanjay K. Srivastava. Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling. Molecular Cancer Therapeutics 2019; 18(10): 1708 doi: 10.1158/1535-7163.MCT-18-1286
|
| 191 |
Hiroaki Sato, Kazuhiro Noma, Toshiaki Ohara, Kento Kawasaki, Masaaki Akai, Teruki Kobayashi, Noriyuki Nishiwaki, Toru Narusaka, Satoshi Komoto, Hajime Kashima, Yuki Katsura, Takuya Kato, Satoru Kikuchi, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Hisataka Kobayashi, Toshiyoshi Fujiwara. Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment. Scientific Reports 2022; 12(1) doi: 10.1038/s41598-022-24313-3
|
| 192 |
Gary Tincknell, Asma Naveed, Jane Nankervis, Ayesha Mukhtiar, Ann-Katrin Piper, Therese M. Becker, Lorraine Chantrill, Morteza Aghmesheh, Kara Lea Vine, Marie Ranson, Daniel Brungs. HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis. Cancers 2022; 14(23): 5754 doi: 10.3390/cancers14235754
|
| 193 |
Hiroto Katoh, Shumpei Ishikawa. Genomic pathobiology of gastric carcinoma. Pathology International 2017; 67(2): 63 doi: 10.1111/pin.12493
|
| 194 |
David Volk, Ganesh Lokesh. Development of Phosphorothioate DNA and DNA Thioaptamers. Biomedicines 2017; 5(3): 41 doi: 10.3390/biomedicines5030041
|
| 195 |
Marta Molina Romero, Emilio José Laserna Mendieta, Gema María Varo Sánchez, María Concepción Alonso-Cerezo, María Orera Clemente. Oncología personalizada: principales biomarcadores en el pronóstico y tratamiento de tumores sólidos. Revista del Laboratorio Clínico 2019; 12(3): e1 doi: 10.1016/j.labcli.2018.11.001
|
| 196 |
Andra M. Sterea, Emmanuel E. Egom, Yassine El Hiani. TRP channels in gastric cancer: New hopes and clinical perspectives. Cell Calcium 2019; 82: 102053 doi: 10.1016/j.ceca.2019.06.007
|
| 197 |
Xiaobo Cai. HER2-targeted ADC DX126-262 combined with chemotherapy demonstrates superior antitumor efficacy in HER2-positive gastric cancer. American Journal of Cancer Research 2024; 14(12): 5752 doi: 10.62347/QCDR9612
|
| 198 |
Yajie Hu, Siyu Liu, Chunhui Cui, Xin Liu, Hui Li, Hong Liu, Shiyao Lu, Zhipeng Lu, Zhiwei Chen, Da Pang, Jian‐Bing Fan, Dongmei Lin, Xianyu Zhang, Yu Sun. Enhanced HER2 status detection in breast and gastric cancers using surrogate DNA methylation markers. IUBMB Life 2025; 77(2) doi: 10.1002/iub.70004
|
| 199 |
Anna Grenda, Kamila Wojas-Krawczyk, Tomasz Skoczylas, Paweł Krawczyk, Jadwiga Sierocińska-Sawa, Grzegorz Wallner, Janusz Milanowski. HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01531-5
|
| 200 |
Tudor Moisoiu, Mihnea P. Dragomir, Stefania D. Iancu, Simon Schallenberg, Giovanni Birolo, Giulio Ferrero, Dan Burghelea, Andrei Stefancu, Ramona G. Cozan, Emilia Licarete, Alessandra Allione, Giuseppe Matullo, Gheorghita Iacob, Zoltán Bálint, Radu I. Badea, Alessio Naccarati, David Horst, Barbara Pardini, Nicolae Leopold, Florin Elec. Combined miRNA and SERS urine liquid biopsy for the point-of-care diagnosis and molecular stratification of bladder cancer. Molecular Medicine 2022; 28(1) doi: 10.1186/s10020-022-00462-z
|
| 201 |
Xingliang Fang, Jinfang Xu, Ketao Jin, Jun Qian. Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: Achievements and limitations. International Immunopharmacology 2023; 118: 110062 doi: 10.1016/j.intimp.2023.110062
|
| 202 |
Eduardo Listik, Ben Horst, Alex Seok Choi, Nam. Y. Lee, Balázs Győrffy, Karthikeyan Mythreye, Donald P. Bottaro. A bioinformatic analysis of the inhibin-betaglycan-endoglin/CD105 network reveals prognostic value in multiple solid tumors. PLOS ONE 2021; 16(4): e0249558 doi: 10.1371/journal.pone.0249558
|
| 203 |
Nicole M. Myer, Kohei Shitara, Hyun C. Chung, Florian Lordick, Ronan J. Kelly, Zsolt Szabo, Z. Alexander Cao, Stephen Leong, David H. Ilson, Wilko Weichert. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. Journal of Cancer Research and Clinical Oncology 2022; 148(8): 2023 doi: 10.1007/s00432-021-03902-1
|
| 204 |
Yasunobu Ishizuka, Takeshi Omori, Naoki Shinno, Masaaki Yamamoto, Hisashi Hara, Tomoyuki Otsuka, Minako Nishio, Naohiro Nishida, Fumie Fujisawa, Naotoshi Sugimoto, Toshinari Yagi, Masahiro Goto, Hiroki Nishikawa, Toshihiro Kudo. Early detection of brain metastases and appropriate local therapy followed by systemic chemotherapy may improve the prognosis of gastric cancer. Scientific Reports 2023; 13(1) doi: 10.1038/s41598-023-46933-z
|
| 205 |
Luhong Yang, Yanxia Wang, Huafeng Wang. Use of immunotherapy in the treatment of gastric cancer (Review). Oncology Letters 2019; doi: 10.3892/ol.2019.10935
|
| 206 |
Minna Voigtlaender, Tanja Schneider-Merck, Martin Trepel. Small Molecules in Oncology. Recent Results in Cancer Research 2018; 211: 19 doi: 10.1007/978-3-319-91442-8_2
|
| 207 |
Daniela S. Allende, Amitabh Srivastava. Gastrointestinal and Liver Pathology. 2024; : 395 doi: 10.1016/B978-0-323-52794-1.00013-4
|
| 208 |
Aditi Damle, Roopa Rachel Paulose, Divya Saikumar, Divya Ail, Niveditha Kartha, Renjitha Bhaskaran, Wesley Jose, Vidhya Jha. Expression of Her2-Neu in Primary Gastric and Gastroesophageal Adenocarcinoma: An Experience from a Tertiary Center in South India. South Asian Journal of Cancer 2023; doi: 10.1055/s-0043-1774290
|
| 209 |
Abdelbaset Buhmeida, Mourad Assidi, Jaudah Al-Maghrabi, Ashraf Dallol, Abdulrahman Sibiany, Mahmoud Al-Ahwal, Adeel Chaudhary, Adel Abuzenadah, Mohammed Al-Qahtani. Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH. Cancer Investigation 2018; 36(2): 129 doi: 10.1080/07357907.2018.1439054
|
| 210 |
Eric Vail, Jianbo Song, Jing Xu, Joseph S. Frye, Jong Taek Kim, Andy Pao, Rhona Schreck, Angela S. Aguiluz, Wenjuan Zhang, Serhan Alkan, Alain Mita, Monica Mita, Robert A. Figlin, David M. Engman, Jean R. Lopategui. Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer. Targeted Oncology 2020; 15(4): 523 doi: 10.1007/s11523-020-00743-9
|
| 211 |
Siyuan Qian, Pedro Villarejo-Campos, Damián García-Olmo. The Role of CAR-T Cells in Peritoneal Carcinomatosis from Gastric Cancer: Rationale, Experimental Work, and Clinical Applications. Journal of Clinical Medicine 2021; 10(21): 5050 doi: 10.3390/jcm10215050
|
| 212 |
Shahid Pervez, Sidra Arshad, Brooj Abro. HER2 Basolateral versus Circumferential IHC Expression Is Dependent on Polarity and Differentiation of Epithelial Cells in Gastric/GE Adenocarcinoma. Pathology Research International 2018; 2018: 1 doi: 10.1155/2018/6246493
|
| 213 |
Zishu Wang, Kaikai Yu, Yudong Hu, Fang Su, Zhenyuan Gao, Ting Hu, Yang Yang, Xiangliao Cao, Feng Qian. Schisantherin A induces cell apoptosis through ROS/JNK signaling pathway in human gastric cancer cells. Biochemical Pharmacology 2020; 173: 113673 doi: 10.1016/j.bcp.2019.113673
|